Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
45.84
+0.43 (0.95%)
At close: Mar 9, 2026, 4:00 PM EDT
45.84
0.00 (0.00%)
After-hours: Mar 9, 2026, 4:04 PM EDT
Royalty Pharma Revenue
In the year 2025, Royalty Pharma had annual revenue of $2.38B with 5.06% growth. Royalty Pharma had revenue of $621.99M in the quarter ending December 31, 2025, with 4.78% growth.
Revenue (ttm)
$2.38B
Revenue Growth
+5.06%
P/S Ratio
11.02
Revenue / Employee
$23,781,930
Employees
100
Market Cap
26.44B
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 5.34B |
| Incyte | 5.14B |
| argenx SE | 4.25B |
| Genmab | 3.72B |
| Alnylam Pharmaceuticals | 3.71B |
| BioNTech SE | 3.70B |
| Moderna | 1.94B |
| Ascendis Pharma | 845.52M |
RPRX News
- 5 days ago - Royalty Pharma plc (RPRX) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 7 days ago - Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform - GlobeNewsWire
- 7 days ago - Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing - GlobeNewsWire
- 10 days ago - Royalty Pharma to Present at TD Cowen's 46th Annual Health Care Conference - GlobeNewsWire
- 21 days ago - Royalty Pharma: 2025 Financial Performance And Strategic Outlook - Seeking Alpha
- 25 days ago - Royalty Pharma: Strong Execution And Visible Pipeline Support Our Buy View - Seeking Alpha
- 25 days ago - Royalty Pharma plc (RPRX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 26 days ago - Royalty Pharma Reports Q4 and Full Year 2025 Results - GlobeNewsWire